Citigroup upgraded it rating on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company’s Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron’s pipeline is not adequately reflected in the current share price. The firm raised its price target for the stock to $390 from $342. Shares of Regeneron (REGN) closed Friday up $1.43 to $329.50.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has a 52 week range of 327.06 – 337.00 and an average volume of 1.25 million. The company is 77% owned by institutions and has an overall market cap of 32.79 million. REGN has an average price target of $347.12 and holds an average recommendation of Overweight, according to FactSet Research.

Wells Fargo downgraded Kinder Morgan Management (NYSE:KMR) to Market Perform from Outperform citing limited near-term catalysts and the potential for negative headline risk from increased scrutiny into Kinder’s presentation of certain financial metrics. Wells lowered its price target range for shares to $66-$71 from $81-$86.

Wells also lowered its price target range for Kinder Morgan Energy (NYSE:KMP) shares to $71-$76 from $81-$86 and for Kinder Morgan (KMI) to $31-$34 from $34-$37. All stocks are now Market Perform rating.

FutureFuel (NYSE:FF) advanced in Monday’s after-hours trade after posting better-than-expected Q4 results. FF surged from 17.98 to a mid-session after-hours high of 21.61 before steadying between 20.54 and 21.52 deeper into the evening. It touched a late high of 21.91.

A pre-market open Tuesday may have potential in the 21.40 to 22 area. Buyers established a tentative near-term floor support in the 21 to 21.44 range, a possible bottom level for longs to watch.